Compare NGNE & DDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGNE | DDD |
|---|---|---|
| Founded | 2003 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.8M | 343.2M |
| IPO Year | 2014 | 2003 |
| Metric | NGNE | DDD |
|---|---|---|
| Price | $31.76 | $3.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $63.57 | $4.75 |
| AVG Volume (30 Days) | 151.5K | ★ 3.9M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 0.93 | ★ 109.79 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $386,902,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $4.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.65 | $1.48 |
| 52 Week High | $37.27 | $3.80 |
| Indicator | NGNE | DDD |
|---|---|---|
| Relative Strength Index (RSI) | 64.15 | 77.17 |
| Support Level | $18.25 | $1.86 |
| Resistance Level | $32.02 | $3.47 |
| Average True Range (ATR) | 2.33 | 0.21 |
| MACD | 0.17 | 0.09 |
| Stochastic Oscillator | 68.50 | 91.84 |
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
3D Systems Corp provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, manufacturing and applications engineering. Its solutions support applications in two key industry verticals: Healthcare Solutions provide surgical planning, implants, instrumentation, and medical education solutions to help medical device manufacturers and healthcare providers accelerate, and ultimately, transform healthcare, and Industrial Solutions which includes aerospace, defense, transportation and general manufacturing. The company operates in the Americas, EMEA, and APAC regions.